Eisai
Eisai and Novartis part ways
January 8, 2013Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva
Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …
Pharma manufacturing news in brief
December 21, 2012Manufacturing and Production Amarin, BASF, Bioden Idec, Eisai, Lonza, Patheon, Sartorious Stedim Biotech, banner pharmacaps
BASF extends offer for ProNova, Patheon closes Banner Pharmacaps deal, plus updates from Amarin, Biogen Idec/Eisai and Lonza.
SMC first to give Fycompa thumbs-up
December 12, 2012Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy
The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …
Eisai opens Fycompa UK manufacturing line
September 25, 2012Manufacturing and Production, Sales and Marketing Eisai, Fycompa
Eisai has opened a new solid dose production line for epilepsy drug Fycompa at its UK base in Hatfield, Hertfordshire. …
UK at centre of Eisai plans
September 18, 2012Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven
Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …
Eisai launches epilepsy drug in UK
September 14, 2012Sales and Marketing Eisai, UK, epilepsy
Eisai has launched its first-in-class epilepsy drug Fycompa in the UK, prior to a roll-out in EU member states including …
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
Eisai to enter Russia with epilepsy launch
June 27, 2012Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy
Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …
Recommendations for two Eisai epilepsy drugs
May 28, 2012Sales and Marketing CHMP, Eisai, Zonegra, epilepsy
European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
NICE rejects Halaven for breast cancer
April 3, 2012Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs. In its final …
Eisai expands UK base
March 21, 2012Sales and Marketing EMEA, Eisai, Hatfield, expansion
Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …
Takeda’s blood pressure treatment Edarbi approved
December 9, 2011Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension
Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …
NICE will not back Eisai’s Halaven
November 17, 2011Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …
Eisai shares risk with novel trial funding approach
September 7, 2011Research and Development Eisai, clinical trials, research and development news
Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial …
